Displaying 1 - 20 of 23
| Active Ingredient | BACLOFEN |
| Therapeutic Class | GABA DERIVED SKELETAL MUSCLE RELAXANTS |
| Indications | Muscle spasm due to multiple sclerosis, spinal cord lesions, and tardive dyskinesia. |
| Caution | Postural hypotension, sedation, dizziness, drowsiness, depression, hallucinations, G.I. disturbances, blurred vision, allergic reactions, muscular weakness. Avoid alcohol. c.f. prescribing in re More ... |
| Dose Range | Adult and children 10 years and over: ½ - 2 tablets increased gradually until the desired effect is reached 3 times daily .Take with food or milk. Paediatric: 300 mcg/kg daily initially in 4 divided doses, increasing gradually every 3 day s |
| Drug Interactions | |
| Pregnancy | Manufacturer advises use only if potential benefit outweighs risk. |
| Breast Feeding | Small amounts are distributed in breastmilk but are not known to be harmful. |
| Active Ingredient | ANTICOAGULANTS |
| Therapeutic Class | ANTICOAGULANTS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | WARFARIN |
| Therapeutic Class | COUMARIN DERIVATIVES |
| Indications | Prophylaxis and treatment of venous thrombus and its extension. Also see information on anticoagulants on p. 186. |
| Caution | Haemorrhage. Prothrombin times should be determined daily at start of therapy. The following drugs may delay coagulation or increase prothombin time. Aspirin, phenylbutazone, tamoxifen, indomethacin, More ... |
| Dose Range | 2-10mg daily for maintenance. |
| Drug Interactions | |
| Pregnancy | Should not be given in pregnancy. Warfarin crosses the placenta with risk of con More ... |
| Breast Feeding | Warfarin is not distributed in breastmilk. |
| Active Ingredient | APIXABAN |
| Therapeutic Class | DIRECT THROMBIN INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | DABIGATRAN |
| Therapeutic Class | DIRECT THROMBIN INHIBITORS |
| Indications | Dabigatran is a direct thrombin inhibitor. It is used for the prophylaxis of venous thromboembolism in patients undergoing orthopaedic surgery and the prevention of stroke and systemic embolisation in More ... |
| Caution | Dabigatran should not be used in patients who are at a high risk for bleeding. It is contraindicated for those patients who have mechanical prosthetic heart valves because of thromboembolism and major More ... |
| Dose Range | Prophylaxis of venous embolism after orthropaedic surgery: Adult: 18-74 years, 110mg to be taken 1-4 hours after surgery, followed by 220mg once daily for 9 days , to be taken 12-24 hours after initial dose. Adult: 75years and older 110mg to be taken afte |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | RIVAROXABAN |
| Therapeutic Class | DIRECT THROMBIN INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | DALTEPARIN |
| Therapeutic Class | HEPARINS |
| Indications | Prophylaxis of ischemic complications and deep vein thrombosis. |
| Caution | See Heparin Sodium. |
| Dose Range |
Thromboprophylaxis in abdominal surgery: 2500-5000 iu s.c. 1-2 hours before surgery then once daily for 5-10 day s after surgery . Unstable Angina: 120 iu/kg to a maximum of 10,000 iu s.c. every 12 hours given with 75-165mg Asp irin daily for 5-8 |
| Drug Interactions | |
| Pregnancy | Not known to be harmful, low molecular weight heparins do not cross the placenta More ... |
| Breast Feeding | Dalteparin is distributed in breastmilk and should be used with caution in lacta More ... |
| Active Ingredient | ENOXAPARIN |
| Therapeutic Class | HEPARINS |
| Indications | Prevention of DVT in orthopedic, abdominal and gynaecologic surgical procedures. May also be used in DVT and pulmonary embolism. |
| Caution | See Heparin. Monitor patients for spinal/epidural bleeding. Nausea, fever, allergic reactions |
| Dose Range | Unstable Angina: 1mg/kg s.c. every 12 hours for 2-12 day s in conjunction with aspirin therap y (100-325mg once a day ) DVT Prophylaxis: 20-40mg s.c. 2 hours p rior to surgery and then every 24 hours or 30mg every 12 hours for 7-1 |
| Drug Interactions | |
| Pregnancy | Pregnancy itself increases the risk of thromboembolism. Pregnant women with a hi More ... |
| Breast Feeding | If enoxaparin therapy is required in nursing women, use of a preservative (benzy More ... |
| Active Ingredient | HEPARIN |
| Therapeutic Class | HEPARINS |
| Indications | Used to prevent thrombus formation or the extension of existing thrombus. |
| Caution | Exercise caution in the elderly and patients with history of pepticulcer. Since heparin is derived from animal tissue use with caution in patients with history of asthma, or allergy. Haemorrhage, More ... |
| Dose Range | DVT: i.v. 5000 units loading dose followed by 18 units/kg/hr given continuously adjusted according to resp onse. Postoperative venous thromboembolism: s.c. 5000 units 2 hours before surgery followed by 5000 units every 8-12 hours for 7 day s or until p |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding | If heparin therapy is required in nursing women, use of a preservative (benzyl a More ... |
| Active Ingredient | CLOPIDOGREL |
| Therapeutic Class | PLATELET AGGREGATION INHIBITORS |
| Indications | Arteriosclerotic vascular disease, cerebrovascular accident, yocardial infarction, peripheral arterial occlusive disease. |
| Caution | The combination of aspirin and clopidogrel in patients with recent stroke who are at risk for recurrent ischemic events has not been shown to be more effective than clopidogrel alone; the combina More ... |
| Dose Range | 75mg once daily. Dosage adjustment is not necessary in moderate renal disease, liver disease or in geriatric patients. Use with caution in severe hepatic or renal impairment. |
| Drug Interactions | |
| Pregnancy | Use with caution. |
| Breast Feeding |
| Active Ingredient | DIPYRIDAMOLE |
| Therapeutic Class | PLATELET AGGREGATION INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | TICAGRELOR |
| Therapeutic Class | PLATELET AGGREGATION INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ALTEPLASE |
| Therapeutic Class | THROMBOLYTIC AGENTS |
| Indications | Intravenous alteplase is effective in producing recanalization of occluded coronary arteries following acute my ocardial infarction. Also effective in the treatment of acute massive pulmonary emboli More ... |
| Caution | Bleeding complications, reperfusion arrhythmias and reinfarction are the primary concerns of therapy . |
| Dose Range | The recommended dose to produce recanalization following my ocardial infarction is 100mg given as a “front -loaded” infusion. |
| Drug Interactions | |
| Pregnancy | Alteplase should be used during pregnancy only when clearly needed. There is a r More ... |
| Breast Feeding |
| Active Ingredient | STREPTOKINASE |
| Therapeutic Class | THROMBOLYTIC AGENTS |
| Indications | Thromboembolic disorders. |
| Caution |
Haemorrhage, allergic reactions, rare- Guillain-Barre syndrome. Due to risk of anaphylaxis, repeated use is contraindicated. |
| Dose Range | 1.5 million units infused over 1 hour as soon as possible after the onset of symptoms. Pulmonary embolism and other arteriovenous occlusions: an initial loading dose of 250 000 units infused intravenously over 30 minutesfollowed by a maintenance dos |
| Drug Interactions | |
| Pregnancy | Avoid use during pregnancy. |
| Breast Feeding |
| Active Ingredient | TENECTEPLASE |
| Therapeutic Class | THROMBOLYTIC AGENTS |
| Indications | As for streptokinase. |
| Caution | As for streptokinase. |
| Dose Range | Adult: Dose is based on body -weight and ranges from 30 mg in patients less than 60 kg to a maximum of 50 mg in those 90 kg or above. |
| Drug Interactions | |
| Pregnancy | Avoid use during pregnancy. |
| Breast Feeding |
| Active Ingredient | EPOIETIN ALPHA |
| Therapeutic Class | HEMATOPOIETIC |
| Indications | Management of symptomatic anaemia associated with chronic renal failure in dialysis and predialysis patients. |
| Caution | Concurrent infection can impair the response to erythropoietin. Aggravation of hypertension (dose-dependent), cardiovascular events, dose-dependent increase in platelet count regressing during treatme More ... |
| Dose Range | Initial dose 50 international units/kg three times weekly, increased at 4-week intervals in increments of 25 units/kg until the target is reached. maintenance 75-300 units/kg once weekly. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | EPOIETIN BETA |
| Therapeutic Class | HEMATOPOIETIC |
| Indications | Management of symptomatic anaemia associated with chronic renal failure in dialysis and predialysis patients |
| Caution | Concurrent infection can impair the response to erythropoietin. Aggravation of hypertension (dose-dependent), cardiovascular events, dose-dependent increase in platelet count regressing during treatme More ... |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | NATEGLINIDE |
| Therapeutic Class | MEGLITINIDES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | REPAGLINIDE |
| Therapeutic Class | MEGLITINIDES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | Metformin/Empagliflozin |
| Therapeutic Class | Sodium Glucose Co-Transporter Inhibitor |
| Indications |
Type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with other antidiabetic drugs or insulin. Empagliflozin, when used in combination with metformin, is also ind More ... |
| Caution | Urinary tract infection ,Decreased vitamin B12 levels; Female genital mycotic infections ;Increased urination ;Male genital mycotic infections; Necrotizing fasciitis of the perineum (Fournier’s gangre More ... |
| Dose Range |
Empagliflozin total daily dose: 10 mg For additional glycemic control, empagliflozin may be increased to maximum total daily dose of 25 mg in patients tolerating 10 mg/day and metformin may be increased to maximum total daily dose of 2,000 mg/day, with gradual escalation to reduce gastrointestinal adverse reactions with metformin |
| Drug Interactions | |
| Pregnancy | Not recommended during second and third trimester of pregnancy based on animal d More ... |
| Breast Feeding | There is no information regarding presence in human milk, the effects on breastf More ... |